These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 18230831)

  • 1. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study.
    van Geest RJ; Sasim IV; Koppeschaar HP; Kalmann R; Stravers SN; Bijlsma WR; Mourits MP
    Eur J Endocrinol; 2008 Feb; 158(2):229-37. PubMed ID: 18230831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
    Kahaly GJ; Pitz S; Hommel G; Dittmar M
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5234-40. PubMed ID: 15998777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of temperature measurement of the eyes by digital infrared thermal imaging as a prognostic factor of methylprednisolone pulse therapy for Graves' ophthalmopathy.
    Shih SR; Li HY; Hsiao YL; Chang TC
    Acta Ophthalmol; 2010 Aug; 88(5):e154-9. PubMed ID: 20553230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
    Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
    Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
    Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
    Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
    Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
    Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
    J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy.
    Matejka G; Vergès B; Vaillant G; Petit JM; Brun-Pacaud A; Rudoni S; Brun JM
    Horm Metab Res; 1998 Feb; 30(2):93-8. PubMed ID: 9543692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
    Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
    Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome.
    Hart RH; Kendall-Taylor P; Crombie A; Perros P
    J Ocul Pharmacol Ther; 2005 Aug; 21(4):328-36. PubMed ID: 16117697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy with large doses of methylprednisolone in Basedow's ophthalmopathy].
    Zbranca E; Mogoş V; Nisfoeanu G; Vulpoi C; Gneazdovschi V; Georgescu D
    Rev Med Chir Soc Med Nat Iasi; 1995; 99(1-2):151-3. PubMed ID: 9524673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
    Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
    Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study.
    Mourits MP; van Kempen-Harteveld ML; García MB; Koppeschaar HP; Tick L; Terwee CB
    Lancet; 2000 Apr; 355(9214):1505-9. PubMed ID: 10801172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
    Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.